Better Therapeutics, Inc. (BTTX)
Market Cap | 16.36K |
Revenue (ttm) | n/a |
Net Income (ttm) | -31.57M |
Shares Out | 54.52M |
EPS (ttm) | -1.15 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 22,838 |
Open | 0.0109 |
Previous Close | 0.0149 |
Day's Range | 0.0003 - 0.0109 |
52-Week Range | 0.0003 - 0.8100 |
Beta | 2.05 |
Analysts | Strong Buy |
Price Target | 6.00 (+1,999,900.0%) |
Earnings Date | May 9, 2024 |
About BTTX
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company’s clinical development candidates are intended to treat cardiometabolic diseases, incl... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for BTTX stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 1,999,900.00% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/e/q/press3-2443395.jpg)
Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
NEW YORK--(BUSINESS WIRE)--Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
![](https://cdn.snapi.dev/images/v1/4/w/press2-2324462.jpg)
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX) (the “Company”) announced today that the Company is terminating its employees and will explore strateg...
![](https://cdn.snapi.dev/images/v1/7/y/press5-2308640.jpg)
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic disease...
![](https://cdn.snapi.dev/images/v1/u/o/press13-2306479.jpg)
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic disease...
![](https://cdn.snapi.dev/images/v1/z/m/press10-2303540.jpg)
Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (Nasdaq:BTTX) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™...
![](https://cdn.snapi.dev/images/v1/s/7/press14-2283734.jpg)
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic disease...
![](https://cdn.snapi.dev/images/v1/6/g/press2-2262198.jpg)
Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases...
![](https://cdn.snapi.dev/images/v1/6/a/press20-2232667.jpg)
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases...
![](https://cdn.snapi.dev/images/v1/v/3/press2-2214799.jpg)
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
SAN FRANCISCO & PALO ALTO, Calif.--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc., a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic dis...
![](https://cdn.snapi.dev/images/v1/d/q/press19-2213030.jpg)
Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, t...
![](https://cdn.snapi.dev/images/v1/k/a/press20-2173643.jpg)
Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, t...
![](https://cdn.snapi.dev/images/v1/p/8/press14-2156432.jpg)
Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, t...
![](https://cdn.snapi.dev/images/v1/v/o/press19-2149267.jpg)
Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today re...
![](https://cdn.snapi.dev/images/v1/r/6/conf15-2146557.jpg)
Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today an...
![](https://cdn.snapi.dev/images/v1/f/y/stocks-to-buy-1600-1898318-2138904.jpg)
Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
![](https://cdn.snapi.dev/images/v1/5/e/press16-2122414.jpg)
Better Therapeutics to Participate in the American College of Lifestyle Medicine's 2023 Annual Conference
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, t...
![](https://cdn.snapi.dev/images/v1/2/m/press10-2104425.jpg)
Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, t...
![](https://cdn.snapi.dev/images/v1/u/o/press18-2098679.jpg)
Better Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, t...
![](https://cdn.snapi.dev/images/v1/m/j/press13-2091110.jpg)
Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, t...
![](https://cdn.snapi.dev/images/v1/b/f/press2-2082771.jpg)
Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, t...
![](https://cdn.snapi.dev/images/v1/r/g/press12-2015637.jpg)
Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today re...
![](https://cdn.snapi.dev/images/v1/a/t/conf12-2002911.jpg)
Better Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 09, 2023
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today an...
![](https://cdn.snapi.dev/images/v1/h/d/press16-1986515.jpg)
Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing software to treat cardiometabolic diseases, today announced that it issued 2,...
![](https://cdn.snapi.dev/images/v1/j/q/press8-1964984.jpg)
Better Therapeutics Receives FDA Authorization for AspyreRx™ to Treat Adults with Type 2 Diabetes
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing software to treat cardiometabolic diseases, today announced that the Food and...
![](https://cdn.snapi.dev/images/v1/k/b/press7-1936976.jpg)
Better Therapeutics Announces Upcoming Poster Presentation at EASL Congress 2023 in Vienna, Austria
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, ...